Caelus Health

Executive Summary

Caelus Health is a Netherlands-based biotechnology company founded in 2019, focused on developing precision probiotic therapeutics for metabolic and inflammatory diseases by modulating the gut microbiome. Its lead program is a probiotic supplement aimed at prediabetes and type 2 diabetes, addressing a large and growing patient population. The company operates in the competitive microbiome space but differentiates through a precision approach. As a private, early-stage biotech, it has yet to disclose total funding or valuation. Near-term value hinges on clinical progress and partnership opportunities. While the therapeutic potential is promising, execution risks remain high, including trial outcomes and financing needs. The company's profile suggests a moderate conviction as a speculative investment, with catalysts such as clinical data readouts and capital raises expected within the next 12–18 months.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 clinical trial results for lead probiotic in prediabetes65% success
• Q3 2026Series B financing round70% success
• H2 2026Pharmaceutical partnership for co-development or licensing40% success